#Obesity medicine
Chronic weight management as a clinical specialty.
HISTORI Semaglutide Record: What We Know
A PubMed record describes a semaglutide trial in schizophrenia, prediabetes, and obesity, but currently supplies no abstract or outcome data.
What 49 Online GLP-1 Prescribers Required
A secret-shopper study found rapid access to GLP-1 prescriptions across 49 US websites, often without direct clinician-patient communication.
MASLD Screening Without a Liver Biopsy
A new review explains how FIB-4 screens for MASLD and MASH in primary care, now that semaglutide and resmetirom can treat confirmed cases.
What Patients Want in an Obesity Drug
A US survey of 800 adults finds route of administration and weight-loss efficacy outweigh simpler dosing rules when picking an obesity medication.
Ozempic Face: What the Research Says
Researchers reviewed 23 resources on GLP-1 drugs and facial volume loss. A peer response says the evidence for a distinct semaglutide effect is weak.
GLP-1 Drugs in Teens: The Nutrition Gap
A pediatric claims study finds nutritional deficiencies in teens on semaglutide and similar GLP-1 drugs, with most never referred for nutrition counseling.
Retatrutide, Prader-Willi and 100 kg Lost
A Prader-Willi syndrome case report describes 108.7 kg lost over 18 months on retatrutide, then oral semaglutide and dulaglutide.
Semaglutide for antipsychotic weight gain
A Danish feasibility trial will test weekly semaglutide in teens with antipsychotic-related obesity.
Semaglutide and Limb Events: What We Know
A new editorial asks whether semaglutide's cardiovascular benefit now extends to limb outcomes in peripheral artery disease.
Semaglutide and Postmenopausal Bleeding
A new case report ties semaglutide to postmenopausal bleeding, but proving cause and effect from one patient is another matter.
GLP-1 use before bariatric surgery
A matched retrospective study linked prior GLP-1RA or tirzepatide use to lower recorded early cardiorenal events after bariatric surgery.
Semaglutide, weight loss and body image
Semaglutide trials measure weight and health outcomes. They cannot promise confidence, happiness, or a particular body-image result.